Abstract
Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 518-522 |
| Number of pages | 5 |
| Journal | Neurological Research |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Jul 2006 |
Fingerprint
Keywords
- Antibodies
- Glioblastoma
- Radioimmunotherapy
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
Radioimmunotherapy of brain tumor. / Paganelli, Giovanni; Bartolomei, Mirco; Grana, Chiara; Ferrari, Mahila; Rocca, Paola; Chinol, Marco.
In: Neurological Research, Vol. 28, No. 5, 07.2006, p. 518-522.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radioimmunotherapy of brain tumor
AU - Paganelli, Giovanni
AU - Bartolomei, Mirco
AU - Grana, Chiara
AU - Ferrari, Mahila
AU - Rocca, Paola
AU - Chinol, Marco
PY - 2006/7
Y1 - 2006/7
N2 - Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.
AB - Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.
KW - Antibodies
KW - Glioblastoma
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=33746528638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746528638&partnerID=8YFLogxK
U2 - 10.1179/016164106X116782
DO - 10.1179/016164106X116782
M3 - Article
C2 - 16808882
AN - SCOPUS:33746528638
VL - 28
SP - 518
EP - 522
JO - Neurological Research
JF - Neurological Research
SN - 0161-6412
IS - 5
ER -